HRSA on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug ...

A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...

Biohaven reports BHV-1300's lowest dose reduced IgG by 60%+ in trial, below analysts' 70-80% target. Drug shows promise for ...

Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.

Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.

McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...

The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...

Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...

The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...

BeiGene acquires MTAP deletion drug SYH2039 from CSPC for $150M, plans combo with BGB-58067, competing with Ideaya's IDE397 ...